Nath Bio-Genes Intrinsic Value
NATHBIOGEN Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹121.44 | ₹97.15 - ₹145.73 | -15.1% | EPS: ₹10.12, Sector P/E: 12x |
| Book Value Method | asset | ₹338.95 | ₹305.06 - ₹372.85 | +136.9% | Book Value/Share: ₹338.95, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹80.84 | ₹72.76 - ₹88.92 | -43.5% | Revenue/Share: ₹101.05, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹126.32 | ₹113.69 - ₹138.95 | -11.7% | EBITDA: ₹40.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹77.93 | ₹62.34 - ₹93.52 | -45.5% | CF Growth: 1.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹64.77 | ₹58.29 - ₹71.25 | -54.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹83.39 | ₹75.05 - ₹91.73 | -41.7% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹277.81 | ₹250.03 - ₹305.59 | +94.2% | EPS: ₹10.12, BVPS: ₹338.95 |
Want to compare with current market value? Check NATHBIOGEN share price latest .
Valuation Comparison Chart
NATHBIOGEN Intrinsic Value Analysis
What is the intrinsic value of NATHBIOGEN?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Nath Bio-Genes (NATHBIOGEN) is ₹121.44 (median value). With the current market price of ₹143.05, this represents a -15.1% variance from our estimated fair value.
The valuation range spans from ₹64.77 to ₹338.95, indicating ₹64.77 - ₹338.95.
Is NATHBIOGEN undervalued or overvalued?
Based on our multi-method analysis, Nath Bio-Genes (NATHBIOGEN) appears to be trading above median value by approximately 15.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 40.59 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 3.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 14.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.19x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Nath Bio-Genes
Additional stock information and data for NATHBIOGEN
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹18 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹75 Cr | ₹62 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹38 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹17 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |